...
首页> 外文期刊>Transfusion: The Journal of the American Association of Blood Banks >Mathematical considerations in the practice of acute normovolemic hemodilution.
【24h】

Mathematical considerations in the practice of acute normovolemic hemodilution.

机译:急性等容血液稀释实践中的数学考虑。

获取原文
获取原文并翻译 | 示例
           

摘要

BACKGROUND: Acute normovolemic hemodilution (ANH) is recommended as a simple and cost-effective method of autologous transfusion. The present mathematical model, based on the current clinical practice of removing 2 to 3 units of fresh whole blood, defines the indications for ANH. STUDY DESIGN AND METHODS: A mathematical model and subsequent nomograms were developed to define patients for whom removal of 2 to 3 units (450 mL each) would allow a theoretical red cell savings equivalent to 1 unit of packed red cells (volume, 250 mL; hematocrit, 60%), that is, a successful application of the technique. Minimal safe target hematocrits were defined as 30, 26, and 22 percent. RESULTS: The minimal initial hematocrits required for given patient weights are displayed on nomograms derived from the mathematical model. The nomograms also indicate the surgical blood loss allowed without ANH: for example, a 75-kg man, (2-unit ANH, minimal safe hematocrit 22%) requires a minimal initial hematocrit of 42 percent (surgical blood loss of 0.64 x estimated blood volume = 3100 mL). CONCLUSION: ANH involving the removal of 2 to 3 units (450 mL each) may be useful in patients with anticipated blood loss exceeding 50 percent of estimated blood volume, high initial hematocrit, and a capacity to tolerate dilution-induced anemia.
机译:背景:急性降血常规血液稀释(ANH)被推荐为一种简单且具有成本效益的自体输血方法。基于目前的临床实践,目前的数学模型是去除2到3个单位的新鲜全血,定义了ANH的适应症。研究设计和方法:建立了数学模型和随后的列线图以定义将2到3个单位(每个450毫升)去除的患者理论上可节省相当于1个单位的红细胞(体积250毫升)的患者。血细胞比容为60%),即该技术的成功应用。最低安全目标血细胞比容定义为30%,26%和22%。结果:给定患者体重所需的最小初始血细胞比容显示在从数学模型得出的列线图上。诺模图还显示了在没有ANH的情况下允许的手术失血:例如,一个75千克的男性(2单位ANH,最小安全血细胞比容为22%)需要的最小初始血细胞比容为42%(手术失血为0.64 x估计血液体积= 3100 mL)。结论:涉及2至3个单位(每个450 mL)去除的ANH可能对预期失血量超过估计血容量的50%,较高的初始血细胞比容和耐受稀释性贫血的能力的患者有用。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号